Mirum dis­con­tin­ues PhI­Ib 'O­hana' study in preg­nan­cy set­ting

One of Mirum Phar­ma­ceu­ti­cals’ three at­tempts to turn around an axed Shire NASH drug has end­ed.

The biotech put out word it will cull a Phase IIb study of the drug volix­i­bat in a liv­er dis­or­der known as in­tra­hep­at­ic cholesta­sis, which im­pedes the prop­er flow of bile acids, caus­ing itch­ing dur­ing preg­nan­cy and po­ten­tial im­pacts on new­borns.

Fi­nal col­lec­tion of the pri­ma­ry out­come da­ta was ex­pect­ed in the first month of 2024, ac­cord­ing to a US gov­ern­ment reg­istry of clin­i­cal tri­als. But “due to the unique chal­lenges in en­roll­ment in the high-risk preg­nan­cy set­ting,” the tri­al will end, the com­pa­ny said in a press re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER